EBA
OCUL icon

Eagle Bay Advisors’s Ocular Therapeutix OCUL Stock Holding History

Eagle Bay Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,777
Closed -$13K – 744
2021
Q4 		$13K Buy
1,777
+977
+122% +$7.59K 0.01% 656
2021
Q3 		$8K Buy
+800
New +$8.98K ﹤0.01% 768

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Eagle Bay Advisors's OCUL Position: Q1 2022 in Review

Eagle Bay Advisors sold out of Ocular Therapeutix (OCUL) in Q1 2022, closing a stake of 1,777 shares — an estimated $13K sold.

Eagle Bay Advisors first reported a position in OCUL in Q3 2021 and held it in 2 quarters. The position peaked at $13K in Q4 2021. 132 funds tracked by Wall St. Rank hold OCUL as of Q1 2022.

  • Eagle Bay Advisors reported no remaining Ocular Therapeutix position as of Q1 2022 after selling out during the quarter.
  • Eagle Bay Advisors sold 1,777 Ocular Therapeutix shares in Q1 2022, an estimated $13K.
  • Eagle Bay Advisors first reported a position in Ocular Therapeutix in Q3 2021 and held it in 2 quarters.
  • Eagle Bay Advisors's Ocular Therapeutix position peaked at $13K in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2022.

Based on Eagle Bay Advisors's 13F filing for Q1 2022, filed 11 May 2022.